GlassScriptPhysician profile
Tushar Sharma
NPI 1891924254
$4,035.79
in general payments reported to CMS, 2019-2025
28 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $235 · 2021: $261 · 2022: $373 · 2023: $1,887 · 2024: $599 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732 · Travel and Lodging: $1,062 · Education: $45.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.82 |
| Travel and Lodging | $1,062.18 |
| Education | $45.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,580.40 | 2023-2025 | Ellipsys Vascular Access System, Advisa Dr Mri Surescan |
| Abbott Laboratories | $404.86 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Eterna, Cardiomems |
| Opko Pharmaceuticals, LLC | $391.89 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $287.27 | 2019-2025 | Jynarque |
| Bard Peripheral Vascular, INC. | $237.06 | 2019-2024 | Fluency Endovascular Stent Graft |
| Astrazeneca Pharmaceuticals LP | $169.35 | 2019-2023 | Farxiga |
| Mallinckrodt Hospital Products INC. | $118.44 | 2022-2024 | Terlivaz |
| Amgen INC. | $97.25 | 2021-2025 | Tavneos, Uplizna |
| Aurinia Pharma U.S., INC. | $96.47 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $90.62 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $79.69 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.69 | 2022 | |
| Cormedix INC. | $51.29 | 2024 | Defencath |
| Glaxosmithkline, LLC. | $45.18 | 2022-2025 | Benlysta |
| Arbor Pharmaceuticals, INC. | $38.87 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $38.46 | 2019 | |
| Horizon Therapeutics Plc | $32.55 | 2019 | |
| Fresenius USA Marketing, INC. | $32.34 | 2022-2023 | Velphoro |
| Alexion Pharmaceuticals, INC. | $25.22 | 2025 | Ultomiris |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $23.86 | 2022 | |
| Boston Scientific Corporation | $22.57 | 2021 | |
| Novo Nordisk INC | $20.38 | 2025 | Ozempic |
| Azurity Pharmaceuticals, INC. | $20.29 | 2024 | Edarbi |
| W. L. Gore & Associates, INC. | $15.07 | 2020 | |
| Vifor Pharma, INC. | $13.20 | 2020 | |
| Smith+Nephew, INC. | $12.93 | 2021 | |
| Cardiovascular Systems INC. | $9.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tushar Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.